|Číslo:||4 / 2013 (Obsah)|
|Autoři:||Prof. MUDr. Milan Kvapil, CSc., MBA|
|Autoři - působiště:||Interní klinika 2. LF UK a FN Motol, Praha|
|Klíčová slova:||sitagliptin, diabetes mellitus 2. typu|
Sitagliptin has been available in the Czech Republic for 5 years. This molecule looks back to the largest evidence base of all gliptins not only in our country, but also worldwide. More than 50 million prescriptions have been recorded globally by the end of 2012. Even this wide use has not be associated with reports of any unusual or unexpected adverse effects. Sitagliptin may be regarded as a gliptin that currently relies on the largest data base demonstrating its safety not only in clinical trials but also in common clinical practice. Its confirmed efficacy is reflected in the range of registered indications recorded in the SPC.
Celý článek je dostupný jen pro předplatitele časopisu